NASDAQ: TCRTAlaunos Therapeutics Inc Stock
$1.76-0.04 (-2.22%)
Updated Aug 21, 2026
TCRT Price
$1.76
Fair Value Price
$0.51
Market Cap
$4.47M
52 Week Low
$1.73
52 Week High
$4.59
P/E
-0.92x
P/B
6.86x
P/S
1,837.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.00k
Earnings
-$4.01M
Gross Margin
100%
Operating Margin
-133,666.67%
Profit Margin
-133,666.7%
Debt to Equity
1.33
Operating Cash Flow
-$3M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TCRT Overview
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TCRT's potential to beat the market
- TCRT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TCRT
RankedUnranked of 470
RankedUnranked of 470
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.24 | A | |
| $122.25 | A | |
| $7.20 | A |
Be the first to know about important TCRT news, forecast changes, insider trades & much more!
TCRT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TCRT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TCRT ($1.76) is overvalued by 245.81% relative to our estimate of its Fair Value price of $0.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TCRT ($1.76) is not significantly undervalued (245.81%) relative to our estimate of its Fair Value price of $0.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TCRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TCRT due diligence checks available for Premium users.
Valuation
TCRT fair value
Fair Value of TCRT stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
$0.51
Overvalued by
245.81%
TCRT ($1.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TCRT ($1.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TCRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TCRT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.92x
Industry
18.13x
Market
18.35x
TCRT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.86x
Industry
5.61x
TCRT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TCRT's financial health
Profit margin
Revenue
$0.0
Net Income
-$952.0k
Profit Margin
0%
TCRT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCRT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.5M
Liabilities
$864.0k
Debt to equity
1.33
TCRT's short-term liabilities ($864.00k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCRT's short-term assets ($666.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCRT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TCRT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$300.0k
Investing
$0.0
Financing
$0.0
TCRT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TCRT vs Biotech Stocks
Alaunos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.